НЕКОНТРОЛИРУМОЕ ПРИМЕНЕНИЕ АНАБОЛИЧЕСКИХ АНДРОГЕННЫХ СТЕРОИДОВ – РАСТУЩАЯ ПРОБЛЕМА ОБЩЕСТВЕННОГО ЗДРАВООХРАНЕНИЯ. ОБЗОР ЛИТЕРАТУРЫ
Введение. Данный обзор посвящен неконтролируемому применению анаболических андрогенных стероидов (ААС) среди непрофессиональных спортсменов. В настоящее время ААС все больше используются не по медицинским назначениям, а для улучшения спортивных результатов, поэтому неконтролируемое использование ААС считается растущей проблемой общественного здравоохранения. Многочисленные исследования показывают, что употребление ААС в немедицинских целях приводит к серьезным проблемам физического и психического здоровья. Были представлены результаты, полученные в различных соответствующих исследованиях.
Кульман С. Нысанбаева1, Наталья Е. Глушкова1, https://orcid.org/0000-0003-1400-8436 Венера А. Абдулла1, Майра К. Бакашева2 1 Казахский Медицинский Университет «Высшая школа общественного здравоохранения», г. Алматы, Республика Казахстан; 2РГКП «Национальный антидопинговый центр», г. Алматы, Республика Казахстан.
Брусникина О. А. Практика применения допинга в профессиональном спорте и последствия для здоровья спортсменов // Национальные интересы: приоритеты и безопасность. 2014. № 268 (31). C. 41–54. 2. Кайргалиев Д.В., Васильев Д.В. и др. История создания анаболических андрогенных стероидов (сильнодействующих веществ) // Современные проблемы науки и образования. 2014. C. 707. 3. Лихоносов Н.П., Бабенко А.Ю. Медицинский аспект использования анаболических андрогенных стероидов у мужчин, посещающих тренажерные залы Санкт-Петербурга // Проблемы эндокринологии. 2019. №65(1). С.19-30. 4. Abbate V.A. et al. Anabolic steroids detected in bodybuilding dietary supplements - A significant risk to public health // Drug Testing and Analysis. 2015. № 7 (7). C. 609–618. 5. Almaiman A.A. et al. Side effects of anabolic steroids used by athletes at Unaizah Gyms, Saudi Arabia: A pilot study // Journal of Sports Medicine and Physical Fitness. 2019. № 3 (59). C. 489–495. 6. Baggish A.L. et al. Cardiovascular toxicity of illicit anabolic-androgenic steroid use // Circulation. 2017. № 21 (135). C. 1991–2002. 7. Barceloux D.G., Palmer R.B. Anabolic-Androgenic Steroids // Disease-a-Month. 2013. № 6 (59). C. 226–248. 8. Beaver K. M. et al. Anabolic-androgenic steroid use and involvement in violent behavior in a nationally representative sample of young adult males in the United States // American Journal of Public Health. 2008. № 12 (98). C. 2185–2187. 9. Bhasin S. et al. The Effects of Supraphysiologic Doses of Testosterone on Muscle Size and Strength in Normal Men // New England Journal of Medicine. 1996. № 1 (335). C. 1–7. 10. Bhasin S. et al. Testosterone dose-response relationships in healthy young men // American Journal of Physiology - Endocrinology and Metabolism. 2001. № 6 44-6 (281). 11. Bolding G., Sherr L., Elford J. Use of anabolic steroids and associated health risks among gay men attending London gyms // Addiction. 2002. № 2 (97). C. 195–203. 12. Buckman J.F., Farris S.G., Yusko D.A. A national study of substance use behaviors among NCAA male athletes who use banned performance enhancing substances // Drug and Alcohol Dependence. 2013. № 1–3 (131). C. 50–55. 13. Casavant M.J. et al. Consequences of Use of Anabolic Androgenic Steroids // Pediatric Clinics of North America. 2007. № 4 (54). C. 677–690. 14. Christou G.A. et al. Acute myocardial infarction in a young bodybuilder taking anabolic androgenic steroids: A case report and critical review of the literature // European Journal of Preventive Cardiology. 2016. Т. 23. № 16. C. 1785–1796. 15. Christou M.A. et al. Effects of Anabolic Androgenic Steroids on the Reproductive System of Athletes and Recreational Users: A Systematic Review and Meta-Analysis // Sports Medicine. 2017. № 9 (47). C. 1869–1883. 16. Christou M.A., Vojvodic M., Xu F.Z., Cai R., Roy M., Fielding J. C. Anabolic-androgenic // Steroid Use Among Gynecomastia Patients. Annals of Plastic Surgery, 2019. 83(3), С.258–263. 17. Cope M.R., Ali A., Bayliss N.C. Biceps rupture in bodybuilders: Three case reports of rupture of the long head of the biceps at the tendon-labrum junction // Journal of Shoulder and Elbow Surgery. 2004. № 5 (13). C. 580–582. 18. Coviello A.D. et al. Effects of graded doses of testosterone on erythropoiesis in healthy young and older men // Journal of Clinical Endocrinology and Metabolism. 2008. № 3 (93). C. 914–919. 19. Coward R.M. et al. Anabolic steroid induced hypogonadism in young men // Journal of Urology. 2013. № 6 (190). C. 2200–2205. 20. Danhaive P.A., Rousseau G.G. Binding of glucocorticoid antagonists to androgen and glucocorticoid hormone receptors in rat skeletal muscle // Journal of Steroid Biochemistry. 1986. № 2 (24). C. 481–487. 21. Evans N.A. Current Concepts in Anabolic-Androgenic Steroids // American Journal of Sports Medicine. 2004. № 2 (32). C. 534–542. 22. Fragkaki A.G. et al. Structural characteristics of anabolic androgenic steroids contributing to binding to the androgen receptor and to their anabolic and androgenic activities Applied modifications in the steroidal structure // Steroids, 2009. 74(2). C. 172–197. 23. Frati P. et al. Anabolic Androgenic Steroid (AAS) Related Deaths: Autoptic, Histopathological and Toxicological Findings // Current Neuropharmacology. 2014. № 1 (13). C. 146–159. 24. Freeman E.R., Bloom D.A., McGuire E.J. A brief history of testosterone // Journal of Urology. 2001. № 2 (165). C. 371–373. 25. Friedman O., Arad E., Amotz O. Ben Body Builder’s Nightmare // Plastic and Reconstructive Surgery - Global Open. 2016. № 9 (4). C. e1040. 26. Gazvani M. R. et al. Conservative management of azoospermia following steroid abuse // Human Reproduction. 1997. № 8 (12). C. 1706–1708. 27. Gruber A.J., Pope H.G. Psychiatric and medical effects of anabolic-androgenic steroid use in women // Psychotherapy and Psychosomatics. 2000. № 1 (69). C. 19–26. 28. Harrison G., Pope, K., David L. Psychiatric and Medical Effects of Anabolic-Androgenic Steroid Use: A Controlled Study of 160 Athletes // Archives of General Psychiatry. 1994. №51(5). Р. 375-382 29. Heuberger J.A.., Cohen A.F. Review of WADA Prohibited Substances: Limited Evidence for Performance-Enhancing Effects // Sports Medicine. 2019. № 4 (49). C. 525–539. 30. Ipеric J., Lu, Debbie H., Barnett, Mitchell J.,Tenerowicz, Michael J.,Vo, Justin C., Perry, Paul J. Psychological and Physical Impact of Anabolic-Androgenic Steroid Dependence // Pharmacotherapy. 2012. № 32(10). Р. 910-919 31. Kanayama G. et al. Ruptured tendons in anabolic-androgenic steroid users // American Journal of Sports Medicine. 2015. № 11 (43). C. 2638–2644. 32. Kersey R.D. et al. National athletic trainers’ association position statement: Anabolic-androgenic steroids // Journal of Athletic Training. 2012. № 5 (47). C. 567–588. 33. Kicman A.T. Pharmacology of anabolic steroids // British Journal of Pharmacology. 2008. № 3 (154). C. 502–521. 34. Kimergård A. et al. Online marketing of synthetic peptide hormones: Poor manufacturing, user safety, and challenges to public health // Drug Testing and Analysis. 2014. № 4 (6). C. 396–398. 35. Lehmann S. et al. Death after misuse of anabolic substances (clenbuterol, stanozolol and metandienone) // Forensic Science International. 2019. (303). 36. Liu J. Di, Wu Y. Q., Cui Y. Anabolic-androgenic steroids and cardiovascular risk // Chinese Medical Journal. 2019. № 18 (132). C. 2229–2236. 37. Lykhonosov M.P., Babenko A.Y. The medical aspect of using anabolic androgenic steroids in males attending gyms of saint-petersburg // Problemy Endokrinologii. 2019. № 1 (65). C. 19–30. 38. McVeigh J., Begley E. Anabolic steroids in the UK: an increasing issue for public health // Drugs: Education, Prevention and Policy. 2017. № 3 (24). C. 278–285. 39. Narducci W.A. et al. Anabolic steroids - A review of the clinical toxicology and diagnostic screening // Clinical Toxicology. 1990. № 3 (28). C. 287–310. 40. Niedfeldt M.W. Anabolic Steroid Effect on the Liver // Current Sports Medicine Reports. 2018. № 3 (17). C. 97–102. 41. Nieschlag E., Vorona E. Doping with anabolic androgenic steroids (AAS): Adverse effects on non-reproductive organs and functions // Reviews in Endocrine and Metabolic Disorders. 2015. № 3 (16). C. 199–211. 42. Nilsson S. et al. The prevalence of the use of androgenic anabolic steroids by adolescents in a county of Sweden // European Journal of Public Health. 2001. № 2 (11). C. 195–197. 43. O’Connor D.B. [и др.]. Exogenous testosterone, aggression, and mood in eugonadal and hypogonadal men // Physiology and Behavior. 2002. № 4 (75). C. 557–566. 44. Parkinson A.B., Evans N.A. Anabolic androgenic steroids: A survey of 500 users // Medicine and Science in Sports and Exercise. 2006. № 4 (38). C. 644–651. 45. Perry P. J. et al. Anabolic steroid use in weightlifters and bodybuilders: An internet survey of drug utilization // Clinical Journal of Sport Medicine. 2005. № 5 (15). C. 326–330. 46. Pope H.G. et al. Adverse health consequences of performance-enhancing drugs: An endocrine society scientific statement // Endocrine Reviews. 2014. Т. 35. № 3. C. 341–375. 47. Rahnema C.D. et al. Anabolic steroid-induced hypogonadism: Diagnosis and treatment // Fertility and Sterility. 2014. № 5 (101). C. 1271–1279. 48. Sagoe D. et al. The global epidemiology of anabolic-androgenic steroid use: A meta-analysis and meta-regression analysis // Annals of Epidemiology. 2014. Т. 24. № 5. C. 383–398. 49. Sjöqvist F., Garle M., Rane A. Use of doping agents, particularly anabolic steroids, in sports and society // The Lancet. 2008. Т. 371. № 9627. C. 1872–1882. 50. Stergiopoulos K. et al. Anabolic steroids, acute myocardial infarction and polycythemia: A case report and review of the literature // Vascular Health and Risk Management. 2008. № 6 (4). C. 1475–1480. 51. Thieme D., Hemmersbach P. Handbook of Experimental Pharmacology: Preface, 2010. C. 460 52. Wold-Anti Doping Agency (WADA) Prohibited List // World Anti-Doping. 2016. № JANUARY. C. 1–116. 53. Richardson A., Antonopoulos G.A. Anabolic-androgenic steroids (AAS) users on AAS use: Negative effects, “code of silence”, and implications for forensic and medical professionals // Journal of Forensic and Legal Medicine, 2019. 68, 101871 54. Solimini R., Rotolo M. C., Mastrobattista L., Mortali C. et al. Hepatotoxicity associated with illicit use of anabolic androgenic steroids in doping // Eur Rev Med Pharmacol Sci: 2017. Vol. 21 - N. 1 P. 7-16 55. Committee opinion No. 484: Performance enhancing anabolic steroid abuse in women // Obstetrics and Gynecology. 2011. Т. 117. № 4. C. 1016–1018.
Количество просмотров: 375

Ключевые слова:

Библиографическая ссылка

Нысанбаева К.С., Глушкова Н.Е., Абдулла В.А., Бакашева М.К. Неконтролирумое применение анаболических андрогенных стероидов – растущая проблема общественного здравоохранения. Обзор литературы // Наука и Здравоохранение. 2021. 3 (Т.23). С. 52-61. doi:10.34689/SH.2021.23.3.006 Nyssanbayeva K.S., Glushkova N.Ye., Abdulla V.A., Bakasheva M.K. Uncontrolled use of anabolic androgenic steroids - a growing public health problem. Literature review // Nauka i Zdravookhranenie [Science & Healthcare]. 2021, (Vol.23) 3, pp. 52-61. doi:10.34689/SH.2021.23.3.006 Нысанбаева К.С., Глушкова Н.Е., Абдулла В.А., Бакашева М.К. Анаболикалық андрогендік стероидтарды бақылаусыз пайдалану – қоғамдық денсаулық сақтаудың өзекті мәселесі. Әдебиетке шолу // Ғылым және Денсаулық сақтау. 2021. 3 (Т.23). Б. 52-61. doi:10.34689/SH.2021.23.3.006

Авторизируйтесь для отправки комментариев